Gates Package — page 263

National Institutes of Health (NIH) B®) nih.gow/research-training/medical-research-initiatives/activ/publications J, Lundgren et al. A neutralizing monoclonal antibody for hospitalized patients with COVID19. New England Journal of Medicine. DOI: 10.1056/NEJMoa2033130 (2020). B. F. Haynes et al., Prospects for a safe COVID-19 vaccine, Sci. Transl. Med. 10.1126/scitranslmed.abeo948 (2020). Grobler, J.A, Anderson, A.S, Fernandes, P., Diamond, M.S, Colvis, C.M, Menetski, J.P, Alvarez, R.M, Young, J.A., Carter, K.L, on behalf of the ACTIV Preclinical Working Group, Accelerated preclinical paths to support rapid development of COVID-19 therapeutics, Cell Host and Microbe (2020), doi: https://doi.org/10.1016/j.chom.2020.09.017 Hewitt, J.A., Lutz, C., Florence, W.C., Pitt, M.L.M., Rao, S., Rappaport, J., Haigwood, N.L., on behalf of theACTIV Preclinical Working Group, ACTIVating Resources for the COVID-19 Pandemic: In vivo Models for Vaccines and Therapeutics, Cell Host and Microbe (2020), doi: https://doi.org/10.1016/j.chom.2020.09.016. Deming ME, Michael NL, Robb M, Cohen MS, Neuzil KM. Accelerating Development of SARS-CoV-2 Vaccines - The Role for Controlled Human Infection Models [published online ahead of print, 2020 Jul 1]. N Engl J Med. 2020;10.1056/NEJMp2020076. doi:10.1056/NEJMp2020076 Collins FS, Stoffels P. Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV): An Unprecedented Partnership for Unprecedented Times [published online ahead of print, 2020 May 18]. JAMA. 2020;10.1001/jama.2020.8920. doi:10.1001/jama.2020.8920 Corey L, Mascola JR, Fauci AS, Collins FS. A strategic approach to COVID-19 vaccine R&D. Science. 2020;368(6494):948-950. doi:10.1126/science.abe5312 This page last reviewed on December 23, 2020 wl